SenegeneBio在B系列募集了110万美元的资金,在Tencent的支持下,扩大其药物研发活动。 SanegeneBio raised $110M in Series B funding, backed by Tencent, to expand its drug development and R&D.

Sanegene Bio在Tencent的支持下,筹集了超过1.1亿美元的B系列资金,以推进其药物开发管道,扩大研发和临床业务,这反映出投资者对中国生物技术部门的强烈信心。 SanegeneBio, backed by Tencent, raised over $110 million in Series B funding to advance its drug development pipeline and expand R&D and clinical operations, reflecting strong investor confidence in China’s biotech sector. 视觉骑士资本为新基金获得了超过5.6亿美元的资金, 针对消费品牌和体验性零售, 由于中国大陆对年轻人驱动的市场的兴趣日益增长. Vision Knight Capital secured more than $560 million for new funds, targeting consumer brands and experiential retail amid growing interest in youth-driven markets in Greater China. 同时,香港投资公司授予Hide Hill公司和其他公司3 900万美元的风险资本授权,这是促进技术创新和加强香港作为区域创新枢纽作用的更广泛努力的一部分。 Meanwhile, the Hong Kong Investment Corporation awarded a $39 million venture capital mandate to Hidden Hill and other firms, part of a broader effort to boost technology innovation and strengthen Hong Kong’s role as a regional innovation hub.